Every 8-K that Buda Juice, Inc. (BUDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BUDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BUDA filings page.
Buda Juice reported strong revenue growth in its first full quarter as a public company but lower profits. For the quarter ended March 31, 2026, revenue rose 17.7% to $3.5 million from $3.0 million, while gross profit edged up to $1.4 million.
Higher selling, general and administrative expenses drove operating income down to $0.6 million from $0.8 million, and net income fell to $0.4 million from $0.8 million, or diluted EPS of $0.03. Non-GAAP net income was $0.6 million, with non-GAAP EPS of $0.05 and Adjusted EBITDA of $0.8 million.
Free cash flow reached $1.1 million, up 37% year over year. Cash on the balance sheet climbed to $19.8 million, largely reflecting $23.0 million of IPO proceeds, net of offering costs and a $3.75 million common stock redemption. The company also highlighted a post-quarter expansion of its Buda Fresh Cherry Limeade into 246 Walmart stores across nine states.
Buda Juice, Inc. reported that Public Ventures, LLC (doing business as MDB Capital), the underwriter of its initial public offering, fully exercised its over-allotment option on January 21, 2026. This option exercise led the company to sell an additional 399,999 shares of common stock.
As a result, Buda Juice received additional gross proceeds of $2,999,992.50 before underwriting discounts, commissions, and offering expenses. This increases the cash raised from its IPO, providing more capital for the company following its recent market debut.
Buda Juice, Inc. reported that it entered into an underwriting agreement for its initial public offering of 2,666,667 common shares at $7.50 per share, for gross proceeds of $20 million before fees and expenses. The underwriters received warrants to purchase 266,667 shares at an exercise price of $9.375 per share, exercisable from July 7, 2026 until January 7, 2031.
The company also adopted the Buda Juice, Inc. 2025 Equity Incentive Plan to grant equity- and cash-based awards to employees, directors, and consultants. Buda Juice issued press releases announcing the IPO pricing and the start of trading of its common stock on the NYSE American exchange.